Brief: Adamis Pharmaceuticals Submits Fast Track Application To FDA For Tempol
10/01/2022 12:38
Jan 10 (Reuters) - Adamis Pharmaceuticals Corp ADMP.O :
* ADAMIS PHARMACEUTICALS SUBMITS FAST TRACK APPLICATION TO
FDA FOR
TEMPOL FOR THE TREATMENT AND PREVENTION OF COVID-19
* ADAMIS PHARMACEUTICALS SUBMITS FAST TRACK APPLICATION TO
FDA FOR
TEMPOL FOR TREATMENT AND PREVENTION OF COVID-19
Source text for Eikon: ID:nGNX1hJ0tc
Further company coverage: ADMP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on DMK Pharmaceuticals
See all newsBrief: Dmk Pharmaceuticals Corp Says Ebrahim Versi Resigned As Chairman
Brief: ZMI Pharma Finalized Acquisition Of All Strategic Assets Necessary To Manufacture Zimhi From Dmk Pharma
Brief: DMK Pharmaceuticals Files For Chapter 11 Bankruptcy In The U.S. - Court Filing
Brief: Dmk Pharmaceuticals Regains Full Rights To Commercialize Zimhi
Brief: DMK Pharmaceuticals Regains Full Rights From US Worldmeds For Symjepi And Provides Corporate Update